Vedolizumab showed a higher overall 1- and 2-year persistence of use compared with two anti–tumor necrosis factor inhibitors in both Crohn’s disease and ulcerative colitis.
MDedge News
Vedolizumab showed a higher overall 1- and 2-year persistence of use compared with two anti–tumor necrosis factor inhibitors in both Crohn’s disease and ulcerative colitis.
MDedge News
